medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effect of the off a grant of the off and the second second



Please review the Supplemental Files folder to review documents not compiled in the PDF.

Interferon Beta-1a ring prophylaxis to reduce household transmission of SARS-CoV-2

Journal:	New England Journal of Medicine
Manuscript ID	Draft
Article Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Castro-Rodriguez, Jose; Pontifical Catholic University of Chile, Pediatrics Fish, Eleanor; Toronto General Research Institute, University Health Network; University of Toronto, Immunology Kollmann, Tobias; Telethon Kids Institute; Perth Children's Hospital, Infectious Diseases Iturriaga, Carolina; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology Karpievitch, Yulia; Telethon Kids Institute; The University of Western Australia, School of Biomedical Sciences Shannon, Casey; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation Chen, Virginia; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation Balshaw, Robert; University of Manitoba College of Medicine, George and Fay Yee Centre for Healthcare Innovation Ben Othman, Rym; Telethon Kids Institute Montgomery, Samuel; Telethon Kids Institute Ho, Joseph; Telethon Kids Institute Gidi-Yunge, Fancisca; Pontifical Catholic University of Chile, School of Dentistry Hartnell, Lucy; Telethon Kids Institute Perez-Mateluna, Guillermo; Pontifical Catholic University of Chile, Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatria, Escuela de Medicina Tebbutt, Scott; UBC; The University of British Columbia Centre for Heart Lung Innovation Garcia-Huidobro, Diego; Pontifical Catholic University of Chile, Department of Family Medicine; University of Minnesota Twin Cities, Department of Family Medicine; University of Chile, Pediatric Infectious Diseases and Immunology Borzutzky, Arturo; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology Borzutzky, Arturo; Pontificial Catholic University of Chile, Pediatric Infectious Diseases and Immunology Borzutzky, Arturo; Pontificial University of Chile, Pediatric Infectious Diseases and Immunology Borzutzky, Arturo; Pontificial University of Chile, Pediatric Infectious Diseases and Immunology Borzutzky, A

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 1 of 32 (which was not certified by peer review) in the editor the off the o

Abstract:	Background Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFNB-1□ could reduce SARS-CoV-2 household transmission. Methods A household cluster randomized controlled study of IFNB-1□ administered to non-hospitalized, symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years compared to standard care, was conducted. Following randomization participants received IFNB-1□ on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary polymerase chain reaction measurements until day 29 in both study arms. A post-hoc `at risk population' was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2. Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii reducing viral transmission to post-exposure household contacts. Results In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFNB-1□ and 565 to standard care. Based on intention to treat and per protocol analyses, IFNB-1□ treatment was ineffective. However, in the `at risk' population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFNB-1□ reduces the probability of SARS-CoV-2 transmission within a household.
-----------	--

SCHOLARONE[™] Manuscripts

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effective of the offee with the preprint in perpetuity. Page 2 of 32 All rights reserved. No reuse allowed without permission.

1 2 3	1	Interferon Beta-1a ring prophylaxis to reduce household transmission of SARS-CoV-2
4 5 6 7	2 3 4	Authors José A. Castro-Rodriguez, PhD Pontifical Catholic University of Chile
8 9 10	5 6	Eleanor N. Fish PhD University of Toronto
10 11 12	7 8	Tobi Kollmann PhD Telethon Kids Institute
13 14 15	9 10	Carolina Iturriaga, RN Pontifical Catholic University of Chile
16 17 18	11 12	Yuliya Karpievitch PhD Telethon Kids Institute
19 20 21	13 14	Casey Shannon BSc Prevention of Organ Failure (PROOF) Centre of Excellence
22 23 24	15 16	Virginia Chen BSc Prevention of Organ Failure (PROOF) Centre of Excellence
25 26	17 18	Robert Balshaw PhD Centre for Healthcare Innovation, University of Manitoba
27 28 29	19 20	Samuel Montgomery PhD Telethon Kids Institute
30 31 32	21 22	Joseph Ho, MSc Telethon Kids Institute
33 34 35	23 24	Rym Ben Othman, PhD Telethon Kids Institute
36 37 38	25 26	Radhouana Aniba, PhD Telethon Kids Institute
39 40	27 28	Francisca Gidi-Yunge, DDS Pontifical Catholic University of Chile
41 42 43	29 30	Lucy Hartnell, MSc Telethon Kids Institute
44 45 46	31 32	Guillermo Pérez-Mateluna, Biotech Pontifical Catholic University of Chile
47 48 49	33 34	Marcela Urzúa, RN Pontifical Catholic University of Chile
50 51 52	35 36	Scott Tebbutt, PhD Prevention of Organ Failure (PROOF) Centre of Excellence
53 54	37 38	Diego García-Huidobro, PhD Pontifical Catholic University of Chile
55 56 57 58	39 40	Cecilia Perret, MD Pontifical Catholic University of Chile
59 60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 3 of 32 (which was not certified by peer revisive) in the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1 2 2	1	Arturo Borzutzky, MD	
3 4 5	2 3	Pontifical Catholic Univers	sity of Chile
6 7	4 5	Telethon Kids Institute	
5 6 7 8 9 10 11 23 14 15 16 7 8 9 10 11 23 24 25 26 27 8 9 30 132 33 45 36 37 8 9 0 41 42 43 44 56 7	3 4 5 6 7	Stephen M. Stick, PhD Telethon Kids Institute Corresponding author:	Professor Stephen Stick dephen.stick@health.wa.gov.au
48 49 50			

Abstract (words 250)

Background Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFNB-1 α could reduce SARS-CoV-2 household transmission. Methods A household cluster randomized controlled study of IFN β -1 α administered to non-hospitalized, symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years

compared to standard care, was conducted. Following randomization participants received IFN β -1 α on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary polymerase chain reaction measurements until day 29 in both study arms. A post-hoc 'at risk population' was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2. Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii) reducing viral transmission to post-exposure household contacts.

Results

In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFNB-1 α and 565 to standard care. Based on intention to treat and per protocol analyses, IFNB-1 α treatment was ineffective. However, in the 'at risk' population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFNB-1 α reduced 56 24 household transmission.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 5 of 32 (which was not certified by peer review) in the editor the other with the oth

1 2 3	1	Conclusion
4 5	2	Ring prophylaxis with IFNß-1 $lpha$ reduces the probability of SARS-CoV-2 transmission within a
6 7	3	household.
7 8 9 10 11 23 14 15 16 7 8 9 10 11 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 11 22 23 24 25 26 7 8 9 0 11 22 23 24 25 26 7 8 9 0 11 22 23 24 25 26 7 8 9 0 12 23 34 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 26 7 8 9 0 12 23 24 25 25 25 25 25 25 25 25 25 25 25 25 25	3	household.
60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effective of the offee with the preprint in perpetuity. Page 6 of 32 All rights reserved. No reuse allowed without permission.

Introduction (Words 3284)

2	The SARS-CoV-2 pandemic has claimed over six million lives. Despite the rapid development and
3	deployment of vaccines in many countries, the number of new cases worldwide still exceeds 500,000
4	daily (https://covid19.who.int). With each wave of the pandemic, health systems have been
5	challenged and the likelihood of emergence of mutant strains of the virus remains. Mutated strains
6	may be more transmissible ^{1,2} , cause more severe disease than the original pandemic strain of SARS-
7	CoV-2 ³ and have the potential to evade available vaccines ^{4,5} . Whilst widespread vaccination has had
8	success limiting the trajectory of the pandemic, the emergence of the omicron variants demonstrated
9	that even with mutations that appear to cause less severe disease ⁶ , high transmission despite
10	immunization could still result in significant pressures on health services ⁷ .
11 12	The solution to halting any pandemic is ending community transmission. During the current
13	pandemic, measures such as healthy hygiene, self-isolation when sick, physical-distancing and use of
14	facemasks have all been effective ⁸ . Moreover, expedited public health responses such as extensive
15	contact-tracing, testing for infection and community lockdowns have all been effective methods to
16	curb transmission ⁹ . International and local border closures plus strict quarantine measures have
17	reduced community transmission to zero for periods in countries such as Australia and New Zealand
18	^{10,11} . However, in these countries and elsewhere, as restrictions are relaxed, localized outbreaks have
19	occurred ¹² that have required rapid, community-wide responses to again supress transmission.
20	Importantly, these community constraints cause unprecedented civil disruption and come at
21	enormous economic ^{13,14} and social costs ^{15,16} .
22	
23	
	Confidential: Destroy when review is complete.
	· · ·

 Since the evolution of dominant SARS-CoV-2 virus cannot be easily predicted ¹⁷, there remains a need to identify interventions that can be rapidly deployed should highly pathogenic strains emerge despite high levels of community immunization. Furthermore, preparations for the next pandemic must include strategies to limit the potential for infection and transmission on first contact with pathogenic respiratory viruses. One of the many therapeutic approaches investigated that appeared clinically useful early in the course of the pandemic was treatment with type 1 interferons (IFNs). Randomized, controlled studies suggest that IFNs offer clinical benefits in moderate ¹⁸ and severe disease ^{19,20} }, reduce the duration of viral shedding ²¹ and prevent infection in front-line hospital workers ²². Nonetheless, IFNs are not generally recommended for treatment of proven cases of Covid-19²³. Since IFNs are sentinel innate immune signalling molecules produced early after first contact with viral pathogens ²⁴⁻²⁶, we postulated that prophylactic IFN treatment might reduce susceptibility to infection of uninfected contacts of individuals with SARS-CoV-2 infection. Such post-exposure prophylaxis could provide non-specific, antiviral protection to curb episodic viral outbreaks ²⁷, help suppress community transmission, even in vaccinated populations, and therefore reduce the risk of emergence of dangerous mutations 4,28. We therefore undertook a cluster, randomized, controlled study of sub-cutaneous pegylated IFN β -1 α (Plegridy. Biogen Inc, Cambridge MA) administration to determine whether IFN β -1 α therapy given to index cases and household contacts can reduce transmission of SARS-CoV-2. 56 23 Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review)诗种用 euthor代hed a wh在 held a grapted mat B 和 a grapted in a constraint in perpetuity. All rights reserved. No reuse allowed without permission. Page 8 of 32

Methods

The Containing Coronavirus Disease-19 (ConCorD-19) trial was a prospective,

cluster, randomized trial of subcutaneous (sc) administration of pegylated IFN β -1 α (Plegridy, Biogen Inc, Switzerland) versus standard care (control)²⁹. Each household of an index case was randomized to either the IFNB-1 α treatment or the standard care control arm. The study was approved by the Institutional Review Board of the Pontificia Universidad Católica de Chile and was registered with clinicaltrials.gov (NCT04552379). All participants provided written informed consent.

Trial population

Index cases were identified from databases of those with confirmed SARS-CoV-2 from COVID-19 clinics and emergency room visits in Santiago, Chile. Households were contacted by telephone to determine eligibility prior to enrolment. Individuals aged between 18 and 80 years who met inclusion and exclusion criteria were deemed as 'eligible' contacts with households only included if there was at least one eligible contact ²⁹. Enrolment and the first doses of IFNB-1 α - if in the intervention arm- had to be within 72 hours of the positive identification of SARS-CoV-2 by polymerase chain reaction (PCR) in index cases. A household was excluded if the index case had been in complete self-guarantine from other household members during the 48 hours prior to the diagnosis of SARS-CoV-2 infection ²⁹. Household characteristics were captured consistent with recommendations of the World Health Organization for assessing household transmission ³⁰. All participants implemented quarantine measures as mandated by local authorities and maintained a daily symptom diary which was collected and reviewed at each study visit by the study team (see online supplementary material). At any time during the trial, if a contact participant developed symptoms suggestive of COVID-19, a 56 23 nasopharyngeal swab was taken by a member of a mobile health team for virus PCR testing in an

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint with was not certified by peer review in the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Page 9 of 32

1 2	1	accredited SARS-CoV-2 diagnostic laboratory. Index cases were instructed to remain in isolation /
3 4 5	2	guarantine for 11 days from onset of symptoms or, if asymptomatic, 11 days from the
5 6 7	З	sample collection date that resulted in the COVID-19 diagnosis. Household contacts remained in
, 8 9	5	
10 11	4	isolation / quarantine for 11 days from date of the sample resulting in the diagnosis of the index case
12 13	5	or of a newly diagnosed household member as per recommendations/rulings by local authorities.
14 15	6	
16 17 18	7	Intervention
19 20	8	A mobile health team conducted home visits of all participant households on study days 1
21 22 23	9	(enrolment), 6, 11, 16 and 29. Index cases and eligible household contacts in the IFNB-1 α arm
24 25	10	received three subcutaneous doses of pegylated IFNß-1 $lpha$ (125µg/0.5ml x 0.5ml) on study days 1, 6
26 27	11	and 11. Ineligible contacts in the IFNB-1 α arm, as well as index cases and all household contacts in
28 29 30	12	the SOC arm, received standard care. All participating households received information regarding
31 32 33	13	hygiene, isolation, social distancing and wearing of facemasks as per public health advice at the time
34 35	14	of enrolment. The IFNB-1 $lpha$ injection was given by a trained member of a mobile health team and
36 37	15	participants were recommended to take paracetamol (1000mg, 6 hourly) commencing at the same
39 40	16	time as the IFNB-1 $lpha$ for up to twenty-four hours, in order to mitigate predictable flu-like symptoms
41 42	17	31.
43 44	18	
45 46	19	Outcomes
47 48	20	The primary outcomes were (i) the proportion of index cases shedding SARS-CoV-2 at study day 11 in
49 50	20	
52 53	21	the IFNIS-1 $lpha$ compared to control arm and (ii) the proportion of household contacts shedding SARS-
55 55	22	CoV-2 at day 11, in the IFNB-1 α compared to the control arm. Secondary and exploratory outcomes
56 57	23	are listed in Supplementary Methods (Supplementary Table 1). Shedding was determined by the
58 59 60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effect of the offee with the preprint in perpetuity. Page 10 of 32 All rights reserved. No reuse allowed without permission.

1 2 3	1	presence of SARS-CoV-2 by PCR in saliva collected on days 1, 6, 11, 16, 21, and 29 (see Supplementary
4 5	2	Methods). A SARS-CoV-2 PCR Ct value ≥40 was considered negative. Viral load was estimated from
6 7 8	3	the Ct value using a standard algorithm (Supplementary Figure 1
9 10	4	
11 12 13	5	Biospecimen collections
14 15	6	The full schedule of biospecimen collection is provided in the supplementary methods
16 17 18	7	(Supplementary Tables 2 and 3. All consenting, non-eligible household contacts also provided
19 20	8	biospecimens according to the schedule collection for non-eligible household contacts.
21 22 23	9	
24 25	10	Adverse events
26 27 28	11	These were classified in accordance with Good Clinical Practice ³² , as non-serious or serious and as
29 30	12	related or unrelated to the trial medication.
31 32 33	13	
34 35	14	Statistical considerations
36 37 38	15	The study was designed at the start of the pandemic and there were few data to guide sample size
39 40	16	calculations. We therefore planned both frequentist inference and Bayesian analyses based on
41 42 43	17	assumptions from the available data.
44 45	18	2
46 47 48	19	Households were randomized as individual clusters using a minimization technique (biased coin,
49 50	20	P=0.7) in order to achieve balance between treatment arms, stratified by the number of people within
51 52 53	21	the household ³³ .
54 55	22	
56 57 58		
59 60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 11 of 32 (which was not certified by peer review) in the editor the discrete with the discrete with

1 2	1	Sample size calculations assumed $\alpha = 0.025$ and power 90% a zero correlation between outcome
3	T	Sample size calculations assumed, α =0.025 and power 50%, a zero correlation between outcome
4 5 6	2	measures and that the household-wise, type 1 error rate would be below 0.05 and power above 80%.
7 8	3	The estimated average household size was 4, based on census data ³⁴ .
9 10	4	
11 12	5	Primary outcomes:
13 14 15	6	(i) SARS-CoV-2 shedding at study day 11 by index cases: Data from Wuhan suggested that the
16 17	7	proportion of untreated index cases still shedding virus on study day 11 would be ~85% ³⁵ . Based on a
18 19 20	8	two tailed Fisher's exact test, a sample size of 278 index cases (139 per arm) would have 90% power
20 21 22	9	to detect a difference in the proportion of individuals shedding virus at study day 11, if the proportion
23 24 25	10	in the IFNß-1 α arm was 65%.
25 26 27	11	
28 29 20	12	(ii) SARS-CoV-2 shedding at study day 11 by household contacts: We estimated the secondary
30 31 32	13	infection rate (transmission within the household) where there is an untreated index case would
33 34 25	14	be 28% ^{36,37} . Based on a stratified Cochran-Mantel-Haenszel test (two-tailed with intra-class
36 37	15	correlation of 0.15), we estimated that a sample of 278 households (834 eligible household contacts)
38 39	16	would have >90% power, at alpha 0.025, to detect an odds ratio of 0.5 for a reduction in transmission
40 41 42	17	to a treated household contact.
43 44	18	
45 46 47	19	Based on these assumptions and estimates, we aimed to recruit 310 households (allowing for a 10%
48 49	20	drop-out rate) and 930 eligible household contacts.
50 51 52	21	
52 53 54 55 56 57	22	We undertook 3 separate sets of analyses:
58 50		
60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) in the determined by the determined by the preprint in perpetuity. Page 12 of 32 All rights reserved. No reuse allowed without permission.

2 3	1	(A) Standard frequentist analyses based on the primary outcomes as stated in the protocol and
4 5	2	described in the Statistical Analysis Plan (available online) and included intention to treat and per
6 7 8	3	protocol approaches .
9 10	4	(B) Exploratory frequentist analyses based on a modified dataset that accounted for biological
11 12	5	implausibility and effects that might only be associated with active treatment (Figure 1 and
13 14 15	6	Supplementary Table 1 for further explanations).
16 17	7	Both frequentist analyses fitted linear mixed effects models using Ime4 ³⁸ (see Statistical Analysis
18 19 20	8	Plan).
21 22	9	(C) Exploratory Bayesian analyses using the same dataset as the exploratory frequentist analysis.
23 24 25	10	Detailed methods are provided in the supplementary methods. Briefly, a generalized linear model
26 27	11	with mixed effects was developed to estimate the probability of infection that is influenced by
28 29 30	12	explanatory variables for each contact case. A stan_glmer with binomial logit function in rstanarm R
31 32	13	package was used ^{39,40} .
33 34 35	14	
36 37	15	The frequentist approach allowed us to estimate the effects of IFNB-1 $lpha$ treatment on the risk of an
38 39	16	individual becoming infected. Whereas the Bayesian analysis allowed us to determine whether the
40 41 42	17	ring prophylaxis strategy using IFNB-1 $lpha$ reduces the probability of transmission within the household
43 44	18	of an infected index case.
45 46 47	19	
48 49	20	With regard to the filtered datasets, we observed, after locking the database, that a number of index
50 51 52	21	cases had negative PCR results on the day of recruitment despite a previous positive diagnostic PCR
53 54	22	test. In the exploratory analyses we therefore excluded households where the index case was
55 56 57	23	unlikely to transmit virus because they were not shedding virus on days 1 and day 6 of the study. We
58 59		
60		Confidential: Destroy when review is complete.

1

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 13 of 32 (which was not certified by peer review) in the eathor (he doe with edge are used in all rights reserved. No reuse allowed without permission.

1		
2 3	1	also excluded households where an eligible contact was already positive at recruitment and there
4 5	2	were no other eligible negative cases in the household. We refer to the modified dataset as the
6 7 8	3	population "at risk". We used the population at risk data to better understand the effects of IFNß-1 $lpha$
8 9 10 11 12 13 14 15 16 17	4	treatment on transmission of virus within households.
	5	
	6	When undertaking these exploratory analyses, we considered effects during two time periods. Days
	7	1-11 (Period 1) i.e., the treatment and isolation period when eligible contacts in the IFNß-1 $lpha$ arm
18 19 20	8	were likely to have elevated IFN levels based on the known pharmacokinetics of pegylated IFNß-1 $lpha$
20 21 22	9	and days 12-29 (Period 2) the post-treatment and isolation period when biological effects of
22 23 24 25 26	10	pegylated IEN β -1 α were likely to be waning in treated individuals. Although samples were not
	11	ebtained on days 12.15, we accured that anyong who became infacted during this paried would
27 28	11	obtained on days 12-15, we assumed that anyone who became infected during this period would
29 30	12	likely still to have a positive PCR on day 16.
32 33	13	
34 35	14	Results
36 37	15	Recruitment, participation, and completion data are shown in Figure 1. Participant demographic and
38 39 40	16	basic household characteristics data are shown in Table 1.
41 42	17	
43 44	18	Between December 2020 and May 2021, three-hundred and forty-one households were enrolled and
45 46 47	19	randomized, of which 137 (IFNB-1 $lpha$ arm) and 151 (control arm) completed the study. Of the 1172
48 49	20	individuals randomized (IFNB-1 $lpha$ arm = 607; Controls = 565), 53 individuals withdrew from the study,
50 51	21	of which 15 were index cases; 35 (14 index cases) in the <code>IFNß-1</code> $lpha$ arm and 18 (1 index case) in the
53 54	22	control arm. The reasons for withdrawal are summarized in the supplementary results
55 56	23	(Supplementary Table 4). One index case withdrew before being allocated to a treatment arm.
57 58		
59 60		Confidential: Destroy when review is complete.

Eighty-two households where the index case had a negative salivary PCR on Day 1 and 6, or where there were no eligible contacts who tested negative at recruitment, were excluded from the exploratory analyses. The remaining households were considered as the 'at risk' population. (Figure 1). (a) Primary analyses The outcomes for the intention to treat (ITT) and per protocol (PP) frequentist analyses were similar (Supplementary Results). There was no effect of IFN β -1 α treatment on duration of viral shedding in those treated (index cases or infected contacts) vs. controls (IC-INF: treatment OR = 0.979, 95%CI =

0.647 to 1.479); IC-ITT: treatment OR = 1.106, 95%CI = 0.657 to 1.863); IC-PP: treatment OR = 1.062,

95%CI = 0.622 to 1.810); Figure 2A). The observed reduction in transmission to household contacts

associated with IFNbeta-1alpha by day 11 was not signif icant (EHC-ITT: treatment OR = 0.582, 95%CI

= 0.271 to 1.247; HC: treatment OR = 0.577, 95%CI = 0.287 to 1.160; EHC-PP: treatment OR = 0.589,

95%CI = 0.272to 1.276; Figure 2B). Vaccination status did not affect these outcomes (Supplementary

results).

(b) Exploratory frequentist analysis of 'At Risk Population.'

Of the at risk population, 33/164 (20%) in the IFN β -1 α arm became infected by day 29 of the study compared to 37/142 (26%) in the control arm (relative risk reduction in the IFN arm = 23%). The majority of the risk reduction occurred during the active treatment phase of the study (days 1 to 11). Treatment with IFNB-1 α was associated with a significant reduction in the odds of a positive saliva PCR for all household contacts compared to standard of care on Day 11 (p = 0.033; OR = 0.550, 95% CI medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 15 of 32 (which was not certified by peer review) in the entropy of the other th

1 2	1	= 0.364 to 0.989). The treatment effect was not significant in the second period (days 12-29) was
3 4	n	(OD = 0.068, 0.064, 0.000, 0
5 6	Z	not significant (OR = 0.968, 95% CI = 0.405 to 2.840) (Figure 2C)
7 8	3	
9 10 11	4	(c) Exploratory Bayesian analysis:
11 12 13	5	Overall, there was a 95% probability of infection reduction within a household by IFNB-1 $lpha$ treatment
14 15	6	and the credible interval for the reduction in transmission probability was in the order of 0.9 to
16 17 18	7	15.9%. During the active treatment period (days 1-11), there was a significant reduction in the odds of
19 20	8	transmission (Bayesian analysis (OR = 0.32, 95% Credible Interval = 0.11 to 0.83). In contrast, in
21 22 22	9	Period 2 (day 12-29), the 95% credible interval of <i>Beta</i> coefficients for the treatment group includes
23 24 25	10	zero and therefore treatment was not effective in this period (Figure 2C, Supplementary Figure 2).
26 27	11	The effect of IFNB-1 $lpha$ on transmission was independent of household size (Supplementary Figure 3)
28 29 30	12	
31 32	13	To determine the effect of IFNB-1 $lpha$ treatment on viral shedding in those who became infected, we
33 34 35	14	examined the viral load trajectories in household contacts who became PCR positive after day 1. We
36 37	15	did not observe any difference in viral load trajectory in those treated with <code>IFNß-1</code> $lpha$ compared to
38 39 40	16	controls (Figure 3A). Furthermore, there was no difference in peak viral load between treated
41 42	17	household contacts and controls who became infected (Figure 3B).
43 44	18	
43 46 47	19	There were fifty-eight serious adverse events in index cases, twenty-seven hospitalizations due to
48 49	20	COVID-19 (25 in the treatment and 32 in the control arm) and was one death in the standard care arm
50 51 52	21	due to COVID-19 in an individual with significant co-morbidities. Twenty-six household contacts of
53 54	22	index cases were hospitalized, 10 in the treatment arm and 16 in the control arm, the difference was
55 56 57 58	23	not statistically significant.
59 60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) in the data with the data with

Discussion

This prospective, household cluster randomized, ring prophylaxis trial demonstrated that pegylated IFNB-1 α may reduce household transmission of SARS-CoV-19. Pegylated IFNB-1 α is an FDA approved therapy for hepatitis C and multiple sclerosis for which the pharmacokinetics and safety profile are well-characterized ⁴¹. The use of this formulation allowed us to predict the likely duration of activity of the three-dose regimen in order to cover the period of peak transmissibility of the virus. Using a mobile medical team to administer doses at home optimized adherence to therapy and allowed reasons for non-adherence and withdrawal to be accurately documented. Although the intention to treat and per protocol analyses failed to demonstrate a significant effect on primary outcomes, these analyses failed to account for index cases not shedding virus at randomization nor an absence of eligible contacts within a household. Using biologically plausible filters to define an at-risk population provided a better understanding of the effects of IFNB-1 α than intention to treat or per protocol analyses. These exploratory analyses that took account of the likelihood that transmission could occur within a household provided a pragmatic assessment of the effects of IFNB-1 α therapy when given to household contacts as prophylaxis. The frequentist analysis of the at-risk populations indicated that *individuals* treated with IFN were less likely to become infected than untreated individuals when exposed to virus with a relative risk

reduction of 23%. The Bayesian analysis revealed that the probability was 95% that transmission was

22 reduced in *households* randomized to IFNB-1 α therapy. This effect of IFNB-1 α on household

23 transmission was only significant during the active treatment period. This highlights the physiological

Confidential: Destroy when review is complete.

importance of IFNB-1 α as a sentinel molecule ²⁴ and provides further evidence for post-exposure prophylaxis with IFN β -1 α as an antiviral strategy. To our knowledge, only one previous study assessed ring prophylaxis in COVID-19. Labhardt et al observed that a combination of lopinavir/ritonavir for 5 days as post-exposure prophylaxis was not effective at preventing infection in close contacts of index cases ⁴². The overall viral load trajectory we observed was very similar to that observed in a laboratory human challenge experiment using wild-type SARS-CoV-2 virus in healthy volunteers ⁴³. Treatment with IFNB-1 α had no effect on viral load trajectory; therefore, reduced viral shedding by infected individuals is unlikely to explain the protective effect on household transmission of IFNB-1 α treatment that we report. Given that treatment affected the probability of transmission only in the active treatment phase and appears unrelated to viral load, we speculate that the observed effects of IFNB- 1α were direct through protection of the at-risk, exposed individual rather than indirectly though effects on the index case. The ConCoRD-19 biorepository will allow further examination of the mechanisms of action of IFN β -1 α on resistance to infection. The study was undertaken prior to the emergence of the omicron strain of virus. We calculated the sample size based upon known household transmission characteristics of the alpha strain which was the dominant strain of the virus early in the pandemic. Simple hygiene measures and guarantine of affected individuals within households could have contributed to lower rates of transmission than expected. Together with a smaller number of eligible household contacts than anticipated from census data, these factors may have reduced the power of the study for the primary outcomes. The

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) in the display of the display of the display the preprint in perpetuity. Page 18 of 32 All rights reserved. No reuse allowed without permission.

effect size observed in this study could be greater for variants with higher transmissibility such as the Omicron strains that are now the dominant worldwide. Nonetheless, the beneficial biological effect of IFN β -1 α treatment was evident in the at-risk population and therefore, post-exposure or ring prophylaxis with IFNB-1 α warrants further investigation, particularly if additional virulent strains of SARS-CoV-2 emerge and for future pandemic virus preparedness. In summary, although intention to treat and per protocol analyses failed to demonstrate significant effects on primary outcomes, in a biologically defined, at risk population, the relative risk of infection for an individual treated with pegylated IFN β -1 α was reduced by 23.0%. Moreover, this is the first study to demonstrate ring prophylaxis with pegylated IFNB-1 α significantly reduces the probability of household transmission of SARS-CoV-2. The effect of pegylated IFNB-1 α was most obvious during the active phase of treatment. In situations where there is emergence of a highly pathogenic and transmissible mutant strain of SARS-CoV-2 despite high vaccination rates, or when there is a new viral pandemic, IFN β -1 α ring prophylaxis could be considered to reduce transmission in households or amongst critical workers and vulnerable communities. Ring prophylaxis with therapies that can interrupt transmission appears to be an effective strategy for highly contagious respiratory viruses. Funding. Biogen PTY Ltd. Supply of interferon as "Plegridy". The study was substantially funded by BHP Holdings Pty Ltd Authorship Authors, Castro-Rodriguez; Fish; Kollmann; Iturriaga, Karpievitch and Shannon contributed equally to the conduct of the study and manuscript as first authors. Authors, Tebbutt, Diego García-Huidobro, Perret, Borzutsky and Stick contributed equally to the conduct of the study and manuscript as senior authors.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 19 of 32 (which was not certified by peer review) in the editor the disclose of the disclose

Acknowledgements

Matthew Cooper (Telethon Kids Institute). Advice regarding protocol and establishment of randomization schedule.

Alexia Foti (Telethon Kids Institute). Collating, reviewing, and editing documents.

.uver). roject management. teter). Assisting collation ant. Zsuzsanna Hollander (PROOF Centre, Vancouver). Statistical advice and statistical analysis plan review.

Nat Eiffler (Telethon Kids Institute). Project management, protocol development, data management.

Jessica Meyer (University of Rochester). Assisting collation and formatting of tables and figures. 18 14

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effect of the offer of the offer of the offer of the offer offe

1 2	1	References
3 4 5	2	1. Alizon S, Haim-Boukobza S, Foulongne V, et al. Rapid spread of the SARS-CoV-2 Delta variant in
6 7 8	3	some French regions, June 2021. Euro Surveill 2021;26(28). DOI: 10.2807/1560-
9 10	4	7917.ES.2021.26.28.2100573.
11 12 13	5	2. Mishra S, Mindermann S, Sharma M, et al. Changing composition of SARS-CoV-2 lineages and rise
14 15	6	of Delta variant in England. EClinicalMedicine 2021;39:101064. DOI: 10.1016/j.eclinm.2021.101064.
16 17	7	3. Twohig K, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for
19 20	8	SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.
21 22	9	Lancet Infectious Diseases 2021. DOI: 10.1016/ S1473-3099(21)00475-8.
23 24 25	10	4. Winger A, Caspari T. The Spike of Concern-The Novel Variants of SARS-CoV-2. Viruses 2021;13(6).
26 27	11	DOI: 10.3390/v13061002.
28 29 30	12	5. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC Transmission in Danish
31 32	13	Households. medRxiv 2021.
33 34 35	14	6. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and
36 37	15	death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a
38 39 40	16	cohort study. Lancet 2022;399(10332):1303-1312. DOI: 10.1016/S0140-6736(22)00462-7.
40 41 42	17	7. Le Rutte E, Shattock A, Chitnis N, Kelly. SL, Penny M. Assessing impact of Omicron on SARS-CoV-2
43 44	18	dynamics and public health burden. medRXiv. Online server: Cold Spring Harbor Laboratory; 2021.
45 46 47	19	8. Centers for Disease Control and Prevention. Implementation of Mitigation Strategies for
48 49	20	Communities with Local COVID-19 Transmission. CDC. May 23 2021.
50 51 52	21	9. Milne GJ, Xie S, Poklepovich D, O'Halloran D, Yap M, Whyatt D. A modelling analysis of the
53 54	22	effectiveness of second wave COVID-19 response strategies in Australia. Sci Rep 2021;11(1):11958.
55 56 57	23	DOI: 10.1038/s41598-021-91418-6.
58 59		Confidential: Destroy when raview is complete
00		connection Destroy methoder beompiete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 21 of 32 (which was not certified by peer review) in the editor the discrete with the discrete with

1 2 3	1	10. National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 38
4 5	2	Reporting period ending 28 March 2021. Commun Dis Intell (2018) 2021;45. DOI:
6 7 8	3	10.33321/cdi.2021.45.19.
9 10	4	11. Houvessou GM, Souza TP, Silveira MFD. Lockdown-type containment measures for COVID-19
11 12 13	5	prevention and control: a descriptive ecological study with data from South Africa, Germany, Brazil,
14 15	6	Spain, United States, Italy and New Zealand, February - August 2020. Epidemiol Serv Saude
16 17 18	7	2021;30(1):e2020513. DOI: 10.1590/S1679-49742021000100025.
19 20	8	12. Conway SR, Lazarski CA, Field NE, et al. SARS-CoV-2-Specific T Cell Responses Are Stronger in
21 22 22	9	Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-
23 24 25	10	CoV-2 Infection. Front Immunol 2021;12:793197. DOI: 10.3389/fimmu.2021.793197.
26 27	11	13. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. JAMA
28 29 30	12	2020;324(15):1495-1496. DOI: 10.1001/jama.2020.19759.
31 32	13	14. Verschuur J, Koks EE, Hall JW. Global economic impacts of COVID-19 lockdown measures stand
33 34 35	14	out in high-frequency shipping data. PLoS One 2021;16(4):e0248818. DOI:
36 37	15	10.1371/journal.pone.0248818.
38 39 40	16	15. Chemen S, Gopalla YN. Lived experiences of older adults living in the community during the
41 42	17	COVID-19 lockdown - The case of mauritius. J Aging Stud 2021;57:100932. DOI:
43 44	18	10.1016/j.jaging.2021.100932.
45 46 47	19	16. Mamun MA. Suicide and Suicidal Behaviors in the Context of COVID-19 Pandemic in Bangladesh:
48 49	20	A Systematic Review. Psychol Res Behav Manag 2021;14:695-704. DOI: 10.2147/PRBM.S315760.
50 51 52	21	17. Callaway E. Beyond Omicron: what's next for COVID's viral evolution. Nature 2021;600(7888):204-
53 54 55	22	207. DOI: 10.1038/d41586-021-03619-8.
56 57		
58 59 60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effect of the offective and the offecti

18. Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-

2	19: A randomized clinical trial. Int Immunopharmacol 2020;88:106903. (In eng). DOI:
3	10.1016/j.intimp.2020.106903.
4	19. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe
5	COVID-19: the COVIFERON randomized controlled trial. Sci Rep 2021;11(1):8059. (In eng). DOI:
6	10.1038/s41598-021-86859-y.
7	20. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and
8	Safety of Interferon β -1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother 2020;64(9)
9	(In eng). DOI: 10.1128/aac.01061-20.
10	21. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with
11	COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med 2021;9(5):498-510. (In
12	eng). DOI: 10.1016/s2213-2600(20)30566-x.
13	22. Meng Z, Wang T, Chen L, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to
14	Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem
15	2021;21(10):920-927. (In eng). DOI: 10.2174/1568026621666210429083050.
16	23. National Institutes of Health. Covid-19 Treatment Guidelines. In: Health NIH, ed.: United States
17	Goverment; 2021.
18	24. Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. Front Immunol 2018;9:2061.
19	DOI: 10.3389/fimmu.2018.02061.
20	25. Mazewski C, Perez RE, Fish EN, Platanias LC. Type I Interferon (IFN)-Regulated Activation of
21	Canonical and Non-Canonical Signaling Pathways. Front Immunol 2020;11:606456. DOI:
22	10.3389/fimmu.2020.606456.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 23 of 32 (which was not certified by peer review) in the entropy of the other th

1		
1 2 3	1	26. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol
4 5	2	2019;43:101300. DOI: 10.1016/j.smim.2019.101300.
1 2 3 4 5 6 7 8 9 101 12 13 14 15 16 17 8 19 20 12 22 32 4 5 26 7 8 9 10 11 22 12 22 32 4 5 26 7 8 9 10 11 22 12 22 32 4 5 26 7 8 9 30 12 33 34 35 36 7 8 9 40 14 24 34 4 5 46 7 8 49 50 15 25 35 4 55 55 55 55 55 55 55 55 55 55 55 55	3	27. World Health Organization. Informal consultation on the role of therapeutics in COVID-19
8 9 10	4	prophylaxis and post-exposure prophylaxis Worl Health Organization.
11 12 12	5	28. Gentile I, Maraolo AE, Piscitelli P, Colao A. COVID-19: Time for Post-Exposure Prophylaxis? Int J
13 14 15	6	Environ Res Public Health 2020;17(11):3997. (In eng). DOI: 10.3390/ijerph17113997.
16 17	7	29. Iturriaga C, Eiffler N, Aniba R, et al. A cluster randomized trial of interferon ss-1a for the reduction
18 19 20	8	of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19).
21 22	9	BMC Infect Dis 2021;21(1):814. DOI: 10.1186/s12879-021-06519-4.
23 24 25	10	30. World Health Organization. Household transmission investigation protocol for 2019-novel
26 27	11	coronavirus (COVID-19) infection. Epidemiological protocol. Geneva: World Health Organization,
28 29 30	12	February 28th 2020 2020. (WHO/2019-nCoV/HHtransmission/2020.4)
31 32	13	(https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-
33 34 35	14	novel-coronavirus-(2019-ncov)-infection).
20 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43	15	31. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally
38 39	16	effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during
40 41 42	17	interferon beta-1a (AVONEX) therapy. Mult Scler 2002;8(1):15-8. DOI: 10.1191/1352458502ms771sr.
43 44	18	32. National Health and Medical Research Council. Guidance: Safety monitoring and reporting in
45 46 47	19	clinical trials involving therapeutic goods. Canberra: National Health and Medical Research Council;
48 49	20	2016.
 45 46 47 48 49 50 51 52 	21	33. Hofmeijer J, Anema PC, van der Tweel I. New algorithm for treatment allocation reduced
53 54	22	selection bias and loss of power in small trials. J Clin Epidemiol 2008;61(2):119-24. DOI:
55 56 57	23	10.1016/j.jclinepi.2007.04.002.
57 58		
59 60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effect of the offer off

1 2 3	1	34. National Institute of Statistics. Chile Population and Housing Census 2017. Santiago, Chile:
4 5	2	National Institute of Statistics (Chile), 2021. (<u>http://ghdx.healthdata.org/record/chile-population-and-</u>
6 7 8	3	housing-census-2017).
9 10	4	35. World Health Organisation. Situation report - 50. Coronavirus disease 2019 (COVID-19) 50. World
11 12 13	5	Health Organisation, 2020. (<u>https://www.who.int/emergencies/diseases/novel-coronavirus-</u>
14 15	6	2019/situation-reports).
16 17	7	36. Yi B, Fen G, Cao D, et al. Epidemiological and clinical characteristics of 214 families with COVID-19
19 20	8	in Wuhan, China. Int J Infect Dis 2021. DOI: 10.1016/j.ijid.2021.02.021.
21 22	9	37. Curmei M, Ilyas A, Evans O, Steinhardt J. Constructing and adjusting estimates for household
23 24 25	10	transmission of SARS-CoV-2 from prior studies, widespread-testing and contact-tracing data. Int J
26 27	11	Epidemiol 2021;50(5):1444-1457. DOI: 10.1093/ije/dyab108.
28 29 30	12	38. Bates DM, M.; Bolker, B.; Walker, S. Fitting linear mixed-effects models using Ime4. Journal of
31 32	13	Statistical Software 2015;67(1):1-48. DOI: doi:10.18637/jss.v067.i01.
33 34 35	14	39. Goodrich B, Gabry J, Ali I, S. B. Bayesian applied regression modeling via Stan. R package version
36 37	15	2.21.1. rstanarm 2020 (<u>https://mc-stan.org/rstanarm</u> .).
38 39 40	16	40. Brilleman SL, Crowther MJ, Moreno-Betancur M, Buros Novik J, Wolfe R. Joint longitudinal and
40 41 42	17	time-to-event models via Stan. StanCon 2018. 10-12 Jan 2018. Pacific Grove C, USA.
43 44	18	https://github.com/stan-dev/stancon_talks/. Joint longitudinal and time-to-event models via Stan
45 46 47	19	StanCon 2018. Pacific Grove, CA, USA2018.
48 49	20	41. Hu X, Seddighzadeh A, Stecher S, et al. Pharmacokinetics, pharmacodynamics, and safety of
50 51 52	21	peginterferon beta-1a in subjects with normal or impaired renal function. J Clin Pharmacol
53 54	22	2015;55(2):179-88. DOI: 10.1002/jcph.390.
55 56 57		
58 59		
60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 25 of 32 (which was not certified by peer review) in the entropy of the other th

1 2	1	42. Labhardt ND, Smit M, Petignat I, et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus
3 4 5	2	Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster
6 7	3	Randomized Trial. EClinicalMedicine 2021;42:101188. DOI: 10.1016/j.eclinm.2021.101188.
8 9 10	4	43. Ben K, Alex M, Mariya K, et al. Nature Portfolio 2022. DOI: 10.21203/rs.3.rs-1121993/v1.
10 11 12	5	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 22 33 34 35 36 37 88 9 40 41 42 43	5	
45 46		
47 48		
49 50 51		
52 53		
54 55		
56 57		
58		
59 60		Confidential: Destroy when review is complete.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the end of the decide with the preprint in perpetuity. Page 26 of 32 All rights reserved. No reuse allowed without permission.

2	
3	
4	
5	
6	
/	
8	
9 10	
10	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
20 27	
27	
20	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
45 11	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
5/	
20 20	
22	
00	

1

	Full study	population	At-risk p	opulation
	SOC	IFN	SOC	IFN
	(n = 565)	(n = 607)	(n = 246)	(n = 293)
Age (years)				
Mean (SD)	35.0 (19.4)	33.2 (18.7)	29.2 (21.0)	29.0 (20.0)
Sex				
Female, n (%)	294	323	133	171
	(52.0%)	(53.2%)	(54.1%)	(58.4%)
Male, n (%)	271	284	113	122
	(48.0%)	(46.8%)	(45.9%)	(41.6%)
Household occupants		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
Mean (SD)	4.10 (1.31)		4.28 (1.30)	4.86 (2.24)
Fully vaccinated for SARS-CoV-2			1	
No, n (%)	380	438	167	217
	(67.3%)	(72.2%)	(67.9%)	(74.1%)

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 27 of 32 (which was not certified by peer review) is the edited to the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

103

169

79 (32.1%) 76 (25.9%)

1	
2 3 4	Yes, n (%)
5 6 7	
7 8 9	Cancer
10 11 12	
13 14 15	No, n (%)
16 17 18 19	
20 21 22	Yes, n (%)
23 24 25 26	Missing, n (%)
27 28 29	Diabetes
30 31 32 33	No, n (%)
34 35 36	
37 38 39	Yes, n (%)
40 41 42 43	Missing, n (%)
44 45 46	Heart disease
47 48 49 50	No, n (%)
51 52 53	
54 55 56 57	Yes, n (%)
58 59 60	

Confidential: Destroy when review is complete.

	(20.3%)	(27.8%)		
Cancer				
No, n (%)	559	598	245	290
	(98.9%)	(98.5%)	(99.6%)	(99.0%)
Yes, n (%)	5 (0.9%)	9 (1.5%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Diabetes	9.			
No, n (%)	542	583	238	285
	(95.9%)	(96.0%)	(96.7%)	(97.3%)
Yes, n (%)	22 (3.9%)	24 (4.0%)	7 (2.8%)	8 (2.7%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Heart disease			2	
No, n (%)	533	578	236	281
	(94.3%)	(95.2%)	(95.9%)	(95.9%)
Yes, n (%)	31 (5.5%)	29 (4.8%)	9 (3.7%)	12 (4.1%)

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the effect of the offee with the preprint in perpetuity. Page 28 of 32 All rights reserved. No reuse allowed without permission.

Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Asthma				
No, n (%)	524	581	230	282
	(92.7%)	(95.7%)	(93.5%)	(96.2%)
Yes , n (%)	40 (7.1%)	26 (4.3%)	15 (6.1%)	11 (3.8%
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Chronic lung disease	Sx.			
No , n (%)	564	606	245	292
	(99.8%)	(99.8%)	(99.6%)	(99.7%)
Yes, n (%)	0 (0%)	1 (0.2%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Chronic kidney disease			R	
No, n (%)	564	604	245	292
	(99.8%)	(99.5%)	(99.6%)	(99.7%)
Yes, n (%)	0 (0%)	3 (0.5%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint Page 29 of 32 (which was not certified by peer review) in the editor the discrete of the discrete

Chronic neurological disease				
No, n (%)	562	602	245	290
	(99.5%)	(99.2%)	(99.6%)	(99.0%)
Yes, n (%)	2 (0.4%)	5 (0.8%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Smoker				
No , n (%)	502	519	227	255
	(88.8%)	(85.5%)	(92.3%)	(87.0%)
Yes, n (%)	63 (11.2%)	88 (14.5%)	19 (7.7%)	38 (13.0%)
Missing, n (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Table 1: Full study population demographics at baseline, and at-risk population demographics

at baseline.

Confidential: Destroy when review is complete.



Figure 1: CONSORT diagram describing participant screening, enrolment, randomisation, and analysis.



1 2 3 4	1	medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint in which was not certified by per review is the author/funder, which as granted medRxiv a ligense to display the preprint in percentity. In ettine treatment of Standa Alfrights reserved. No revise allowed without permission. Exploratory frequentist
5 6 7	2	and Bayesian analysis, to determine if IFN is associated with a reduction in the number of
8 9 10 11	3	positive COVID-19 tests in household contacts across study period 1 (days 1-11) and
12 13 14	4	study period 2 (days 12-29). Treatment with IFN is associated with a significant reduction
15 16 17 18	5	in the odds of a positive COVID-19 test for all household contacts compared to standard of
19 20 21	6	care; frequentist analysis (p = 0.033; OR = 0.550, 95% CI = 0.364 to 0.989), Bayesian
22 23 24 25	7	analysis (OR = 0.32, 95% CrI = 0.11 to 0.83). IC-INF = Infected case population (main
26 27 28	8	analysis), IC-ITT = Index case – intention to treat population (sensitivity analysis 7.1.3.2),
29 30 31	9	IC-PP = Index case – per protocol population (sensitivity analysis 7.1.3.3). EHC-ITT =
33 34 35	10	Treatment-eligible household contact – intention to treat population (main analysis), HC =
36 37 38 30	11	Household contact (eligible + non-eligible contacts) population (sensitivity analysis
40 41 42	12	7.2.3.2), EHC-PP = Treatment-eligible household contact = per protocol population
43 44 45	13	(sensitivity analysis 7.2.3.3). * p < 0.05.
40 47 48 49	14	
50 51 52		
55 54 55		
50 57 58		
59 60		

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse **B**owed without permispion. SOC log10 viral load (cp/mL) **IFN** og10 viral load (cp/mL) soc IFN **Study Day** Figure 3: Log₁₀ viral load in study participants who test positive for COVID-19 after visit 1. (A) No significant difference in median viral load at each study visit between SOC and IFN arms. (B) No significant difference in peak viral load between SOC and IFN arms. SOC = standard of care arm, IFN = interferon arm, cp/mL = copies/mL. n = 57 (IFN) & n = 61 (SOC) participants per group. for Review

Interferon Beta-1a ring prophylaxis to reduce household transmission of SARS-CoV-2

Supplementary Materials

Table of Contents

List of Study Investigators
Supplementary Methods
Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-28
Viral load calculation
Populations used for analyses
Bayesian statistical analysis9
Bayesian model10
Computation of difference in probability of infection in IFN vs SOC arms10
Supplementary Results
Bayesian analysis of infection reduction
Supplementary Figures
Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load13
Supplementary Figure 2 Distribution of the difference in probability of infection between SOC and
IFN arms by household size14
Supplementary Figure 3: Distribution of the difference in probability of infection between SOC and
IFN arms14
Supplementary Tables15
Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing
Coronavirus Disease-19 clinical trial17
Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible
household contacts

Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household
contacts
Supplementary Table 4: Study withdrawal reasons by treatment arm
Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons
for declined participation following invitation to participate in ConCorD-1921
Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis.
Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN,
with average values and 95% credible intervals24
Supplementary Table 8: Difference in probability of infection in each study period irrespective of
household size24
Supplementary Table 9: Difference in probability of infection in each study period, stratifying by
household size25
Supplementary Table 10: Number of contacts at each household size
Supplementary References
Supplementary Appendices

List of Study Investigators

Jose A. Castro-Rodriguez

Department of Pediatric Pulmonology, School of Medicine, Pontificia Universidad Católica de Chile,

Santiago, Chile

Eleanor N. Fish

Department of Immunology, University of Toronto, Toronto, Canada

Toronto General Hospital Research Institute, University Health Network, Toronto, Canada

Tobias Kollman

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Carolina Iturriaga

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia

Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Yuliya Karpievitch

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

School of Biomedical Sciences, University of Western Australia, Nedlands, Australia

Casey Shannon

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Robert Balshaw

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Virginia Chen

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Samuel T. Montgomery

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

School of Population Health, Curtin University, Bentley, Australia

Joseph Ho

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Rad Aniba

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Rym Ben Othman

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Francisca Gidi-Yunge

School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Lucy Hartnell

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Guillermo Pérez-Mateluna

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica De Chile, Santiago, Chile

Marcela Urzúa

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia

Universidad Católica De Chile, Santiago, Chile

Scott Tebbit

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Diego García-Huidobro

Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile,

Santiago, Chile

Department of Family Medicine and Community Health, University of Minnesota, United States of America

Cecilia Perret

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile

Arturo Borzutzky

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Stephen M. Stick

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,

Nedlands, Australia

Perth Children's Hospital, Nedlands, Australia

Supplementary Methods

Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2

RNA extraction and RT-qPCR for SARS-CoV-2 detection was performed at the Infectiology and Molecular Virology Laboratory, Red Salud UC Christus, Santiago, Chile. RNA was extracted in parallel from saliva using the MagBind RNA extraction kit (#GN7101907, Maccura Biotechnology, Rockville, MD, USA) with the Auto-Pure 32A Nucleic Purification System (Maccura Biotechnology, Rockville, MD, USA), and using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Real-time PCR amplification was performed using the LightMix Modular Wuhan CoV RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) targeting the RNA-dependent RNA polymerase (RdRP) gene, targeting SARS-COV-2, but not other SARS-like viruses (CoVNL63, CoV229E, HKE, OC43, MERS), with a positive control containing three separate diagnostic targets (E gene, N gene, RdRP). The reverse transcription and PCR processes occur in a single step in a real-time thermocycler (Lightcycler 480 II, Roche, Berlin, DE) with an analytical sensitivity of 10.6 copies per reaction. A cycle threshold (Ct) value of ≤ 37 was considered positive for SARS-CoV-2.

Viral load calculation

The viral load of SARS-CoV-2 detected in saliva was calculated using a standard curve. A commercial SARS-CoV-2 standard (#COV019, Exact Diagnostics, Fort Worth, TX, USA) at a concentration of 200,000 copies per mL (cp/mL) was extracted in triplicate using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Following extraction, serial dilutions (1:10; 200,000cp/mL to 20cp/mL & 1:5; 200,000cp/mL to 64cp/mL) were used in triplicate for reverse transcription and RT-qPCR using the LightMix Modular Wuhan CoV

RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) with the Lightcycler 480 II thermocycler (Roche, Berlin, DE), resulting in 9 replicates at each concentration. SARS-CoV-2 was detectable in all nine replicates at 200,000cp/mL, 40,000cp/mL, 20,000cp/mL, 8,000cp/mL, 2000cp/mL, and 1,600cp/mL, and a standard curve was generated using the mean Ct values for these concentrations (Supplementary Figure 1) to calculate SARS-CoV-2 viral load in samples of unknown titre, resulting in a lower limit of quantification of 1,600cp/mL.

Populations used for analyses

Participants were excluded for analysis as outlined in the statistical analysis plan, or as outlined in the exploratory analysis (Supplementary Appendix B). Total households and participants excluded and used in each population are described in Supplementary Table 6. Briefly, participants were excluded from the populations used in the primary analyses (IC-INF, IC-ITT, EHC-ITT, HC) if the study visit was not performed, or was performed outside the +/– 1 day window either side of the scheduled visit date (Statistical Analysis Plan 6.5). Participants who didn't complete the full course of the treatment were excluded from the Per Protocol populations used in the primary analyses (IC-PP, EHC-PP). In the exploratory analysis, whole households were excluded if the index case was SARS-CoV-2 negative via salivary PCR at study days 1 & 6, and if there were no SARS-CoV-2 negative eligible or ineligible contacts in the household at study day 1. Participants were then excluded from the exploratory analysis if they were SARS-CoV-2 positive via salivary PCR at study day 1. Participants were then excluded from the exploratory analysis where household size was greater than 7, as these household sizes were unable to be modelled using Bayesian modelling.

Bayesian statistical analysis

Bayesian analysis was included in the original statistical analysis plan. The goal was to test the null hypothesis that treatment of household contacts with IFN β -1 α does not reduce the probability of transmission from an infected index case to household contacts. As outlined in the analysis plan, we

used data to develop a data generating process governed by probabilities that a household contact of an index case would test positive to COVID-19, and non-informative prior was used.

Bayesian model

A generalized linear model with mixed effects was developed to estimate the probability of infection for each contact. A stan_glmer with binomial logit function from the rstanarm package (1) was run using R (version 4.1.1) to obtain Beta coefficients for 4,000 simulated samples to estimate the probability of infection using the following model:

$$pcr \sim (1 \mid index) + vacc + viral + infected + eligible + sex + age + arm$$

where: *pcr*: binary COVID-19 test result, *index*: index case in the household – treated as a random effect, *vacc*: number of vaccinated household members, *viral*: log₁₀ viral load of the index case at the beginning of the period, *infected*: number of COVID-19 positive household members at the beginning of the period, *eligible*: whether the household contact was eligible for treatment, *sex*: sex of the household contact, *age*: age of the household contact, and *arm*: study arm (i.e. SOC/IFN) of the household were the fixed explanatory variables.

The features of the model were the same as the exploratory frequentist analysis, with the exception of adding the treatment period as a feature. Instead, the Bayesian analysis split the data into two periods (Period 1: study days 1–11, Period 2: study days 12–29) with analysis conducted separately. For period 2, COVID-19 positivity at day 11 was used to determine COVID-19 positive household members at the beginning of the period. The population used for analysis was the same as the "At-risk" population used in the exploratory frequentist analysis (Supplementary Table 6), with the additional exclusion of participants in households with a size larger than 8.

Computation of difference in probability of infection in IFN vs SOC arms

In each simulation, we obtained a PCR outcome for each contact from the Bayesian model by applying the posterior_predict function in the rstanarm package to the observed data (1). We further computed the percent of infections in each treatment arm irrespective of household size (Supplementary Table 8) and for each household size (Supplementary Table 9). Furthermore, we computed the difference in probability of infection by subtracting the probability of infection in IFN arm from the probability of infection in SOC arm. As a results, we obtained 4000 differences (irrespective of household size) and 4000 differences for each household size

Significance of the treatment effect was determined by 95% credible interval (CrI) for the treatment Beta coefficient. If 0 was included in the CrI, the effect of treatment group was considered not significant. Average Beta coefficient and odds ratio for the effect of the IFN treatment as compared to SOC were computed in each study period. The average odds ratio of being infected with SARS-CoV-2 on IFN treatment vs. SOC was calculated by exponentiating the values of the average of the coefficients (Supplementary Table 7).

Supplementary Results

Bayesian analysis of infection reduction

Treatment with IFN had a significant effect in study period 1 as the 95% CrI for treatment coefficient did not include zero (Supplementary Table 7). However, IFN treatment did not have a significant effect in period 2 as the 95% CrI did include zero (Supplementary Table 7).

In study period 1, there was 95% probability of infection reduction between 0.9% to 15.9% due to the IFN treatment, with 8.5% median and mean infection reduction (Supplementary Table 8). In study period 2, there are 95% probability of infection reduction -6.7% to 4.8% due to the IFN treatment, with -9% of median and mean of infection reduction (Supplementary Table 8).

When we stratified the infection reduction by household size, only households' size 3 and 4 in period 1 had a 95% CrI without zero (Supplementary Table 9).

As the distribution of Bayesian estimated differences in probabilities of infection in study period 1 is centred to the right of 0 (Supplementary Figure 3A), IFN treatment had an effect on reducing SARS-CoV-2 transmission within households. However, as the distribution in study period 2 is centred around 0, it suggests IFN has no effect on SARS-CoV-2 transmission within households (Supplementary Figure 3B).

Supplementary Figures



Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load. Mean cycle

threshold (Ct) values are plotted on the y-axis, and log_{10} SARS-CoV-2 copies per mL (cp/mL) are plotted on the x-axis. Linear regression resulted in an R² value of 0.9972, to fit the equation y = -3.719x + 48.83.



Supplementary Figure 2: Distribution of the difference in probability of infection between SOC and IFN arms. (A) Distribution in study period 1, and (B) Distribution in study period 2. Vertical black line represents zero difference in probability of infection between SOC and IFN arms.



and IFN arms by household size. (A) Distribution in study period 1, and (B) Distribution in study period 2. Vertical dashed black line represents zero difference in probability of infection between SOC and IFN arms.

Supplementary Tables

Primary Objectives	Outcome & Outcome Measure				
To determine whether IFN β -1 α treatment reduces the proportion of	The proportion of index cases shedding SARS-CoV-2 at day 11 in the				
infected cases shedding SARS-CoV-2 at day 11 after randomization.	active arm compared to the standard of care arm				
To determine whether IFN β -1 α treatment reduces the incidence of					
SARS-CoV-2 transmission from index cases to treatment-eligible					
household contacts, as measured by any positive upper airway infection	The proportion of household contacts shedding SARS-CoV-2 at day 11				
evidenced by real-time Polymerase Chain Reaction (RT-PCR), in	in the active arm compared to the standard of care arm				
contacts at day 11 after randomization.					
Secondary Objectives	Outcome & Outcome Measure				
To determine whether in index cases infected with SARS-CoV-2, IFN β -					
1α treatment compared with standard of care reduces the duration of	Duration (in days) of SARS-CoV-2 measured by PCR of samples taken				
SARS-CoV-2 upper airway virus shedding over 28 days following	on study days 1, 6, 11, 16, 21, and 29				
randomization.					

	Number of household contacts of participants in the IFN arm with
To determine whether IFN β -1 α treatment affects the incidence of SARS-	
	positive upper airway PCR compared to that in the standard of care arm
CoV-2 upper airway infection or serological conversion by study day 29	
	at day 1 & 11, and seroconversion (IgM) over the study period up to day
in household contacts.	20
	29
To determine whether IFN β -1 α treatment compared with standard of	The proportion of infected cases in the active arm that are hospitalized or
care reduces the proportion of infected cases that require hospital	die due to COVID-19, as compared to the proportion in the standard of
admission or die due to COVID-19	care arm
To determine the sofety of IFN 0 1 win the tweety out and approximation of	In siden as and associate of non-outed advance execute in the extinct and
To determine the safety of IFIN p-1a in the treatment and prevention of	incluence and severity of reported adverse events in the active arm
SARS-CoV-2 infection	compared to the standard of care arm
	1
	Biological samples and associated data will be stored for later access
Exploratory Objectives	for ethically approved research relevant to the exploratory objectives
Assess the impact of participant demographic and clinical metadata on the	viral transmission dynamics and response to IFN β -1 α in the household

using unbiased systems epidemiology

Assess the impact of host biology on the viral transmission dynamics and response to IFN β -1 α in the household using unbiased systems biology

Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or

exposure, as well as response to IFN β -1 α intervention

Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN β -1 α intervention

Estimate the secondary infection rate, serial interval, incubation period, duration of infectiousness, duration of detected shedding

Individual level: SARS-CoV-2 shedding as determined by PCR of upper respiratory samples analyzed as a function of time of exposure relative to

the start of the intervention

Household/Community level: While each study arm will be assessed independently of each other as secondary objectives, we will assess the impact

of any intervention on the entire household. When demographic and/or biological variables

Host immune response (anti SARS-CoV-2 antibodies, blood cytokines and chemokines), as well as blood and nasal mucosal host response (including

but not limited to transcriptomics, metabolomics, proteomics, and epigenomics) to IFN β-1α intervention, SARS-CoV-2 infection and their

interaction

Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Extra Visit – Suspected COVID-19
Study Day	1	6	11	16	21	29	
	Dose 1	Dose 2	Dose 3				
Blood Samples							
Complete Blood count/ ESR	Х					Х	X
SARS-CoV-2 antibodies (IgGAM)	X					X	
Study sample 1	X	X	X			X	X
Study sample 2	X	X	X			X	X
Study sample 3	X	X	X			X	X
Airway samples							
Nasal brush	X						
Nasal lining fluid	X	X	X				
Airway Swab for COVID-19 diagnosis							X
Saliva Samples							
Saliva	X	X	X	X	X	X	X

Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Extra Visit – Suspected COVID-19
Study Day	1	6	11	16	21	29	
	Dose 1	Dose 2	Dose 3				
Blood Samples							
Complete Blood count/ ESR							X
SARS-CoV-2 antibodies (IgGAM)						X	
Study sample 1						X	X
Study sample 2						X	X
Study sample 3						X	X
Airway samples							
Nasal brush	X						
Nasal lining fluid	X	X	X				
Airway Swab for COVID-19 diagnosis							X
Saliva Samples							
Saliva	X	X	X	X	X	X	X

Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts.

Interferon arm										Standard of Care arm									
			Da	ys sir	ice ei	nrolm	ent						Da	ys sin	ice er	nrolm	ent		
Withdrawal reason	3	4	5	10	11	14	15	21	28	Withdrawal reason	3	4	5	10	11	14	15	25	28
Family withdrew	0	0	5	0	0	2	0	0	0	Family withdrew	0	0	2	0	0	0	0	0	0
Interpersonal problems	0	0	3	0	0	0	0	0	0	Interpersonal problems	0	4	0	0	0	0	0	0	0
Lack of time	0	1	0	0	0	0	0	0	0	Lack of time	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	Other	0	0	1	0	0	0	0	0	0
Parental decision	0	0	2	0	0	0	0	0	0	Parental decision	0	0	0	0	0	0	0	0	0
Poor health	0	0	1	0	0	1	0	0	0	Poor health	0	0	0	0	0	0	0	0	0
Sample collection problems	0	0	0	0	0	0	0	0	0	Sample collection problems	0	0	1	0	0	0	0	0	0
Side effects of drug	0	0	0	0	0	2	0	0	0	Side effects of drug	0	0	0	0	0	0	0	0	0
Uninterested	0	0	0	1	0	0	0	0	1	Uninterested	0	0	0	0	0	0	0	0	0
Unspecified	4	3	1	2	1	0	0	0	0	Unspecified	0	1	3	0	0	0	1	5	0
Work commitments	0	0	2	2	0	0	0	0	0	Work commitments	0	0	0	0	0	0	0	0	0

Supplementary Table 4: Study withdrawal reasons by treatment arm.

Unable to be contacted	736
Days of symptoms > 5	777
Asymptomatic	306
Isolating from household contacts	219
Hospitalized	177
Confirmation of COVID-19 took longer than 72 hours	35
Deceased	2
Ineligible medical condition or treatment	67
Less than 18 years old	54
Pregnant, or plans on becoming pregnant	32
Previously infected with COVID-19	36
Greater than 80 years old	3
All eligible household contacts currently infected	514
Does not live with eligible household contact	412
Not the first infection in the household	392
Does not live in the Santiago metropolitan area	20
Reasons for not participating in ConCorD-19	
Index case declined	835
Eligible household contact declined	196
Total	4813

nodRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276360; this version posted June 14, 2022. The copyright holder for this preprint Reissons for eaviet by one from Concentration of the copyright holder for this preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19.

Analyses	outlined in SAP	Exclusions	Participants (n) included for analyses				
Analysis	Population	Reason	Participants (n)		IFN	SOC	
				IC	172	169	
	Full study			ЕНС	177	165	
	population			СР-НС	80	81	
				IHC	178	150	
Primary 1 -	IC-INF at day 11	No visit	22	IC	159	164	
Main		Visit outside window	3	СР-НС	69	76	
Primary 1 –	IC-ITT at day 11	No visit	12	IC	159	164	
Sensitivity 1		Visit outside window	2		107	104	
Primary 1 –	IC-PP at day 11	No visit or protocol deviation	26	IC	146	164	
Sensitivity 2		Visit outside window	1		110		
Primary 2 –	EHC-ITT at day	No visit	20	ЕНС	166	156	
Main	11		20	Line	100	150	
Primary 2 –	HC at day 11	No visit	37	ЕНС	166	156	
Sensitivity 1			2.	IHC	168	143	

Primary 2 – Sensitivity 2	EHC-PP at day 11	No visit or	ЕНС	156	156		
Explora	tory Analyses	Exc					
Analysis	Population	Reason	Households (n)	Participants (n)			
	Household	COVID-negative index case	33		ЕНС	164	142
Frequentist	contacts, COVID-	No household contacts at risk	49				
•	19 negative at	Household contact COVID		43	ІНС	129	104
	study day 1	positive					
	Frequentist				ЕНС	152	139
Bayesian	population,	Household size > 7	5	61	IHC	113	104
	household size ≤ 7					-	

Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis. IC: index case, EHC: Treatment eligible household contacts, CP-HC: COVID-19 positive household contacts, IHC: Treatment ineligible household contacts, IC-INF: IC & CP-HC, IC-ITT: Index case – intention to treat population, IC-PP: Index case – per protocol population, EHC-ITT: Treatment eligible household contacts – intention to treat population, HC: EHC and IHC, EHC-PP: Treatment eligible household contact – per protocol population.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (whit is a logification of the previous of the p

Study pariod	Maan	Standard Doviation	Lower limit	Upper limit	
Study period	Mean		(2.5%)	(97.5%)	
1	-1.17	0.52	-2.23	-0.19	
2	0.27	0.55	-0.80	1.36	

Odds ratio for treatment with IFN

95% Credible Intervals

Cturder a suite d	Maar	Standard Deviation	Lower limit	Upper limit	
Study period	Mean	Standard Deviation	(2.5%)	(97.5%)	
1	0.32	1.68	0.11	0.83	
2	1.31	1.73	0.45	3.90	

Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.

Study period	2.5%	25%	50%	Mean	75%	97.5%
1	0.009	0.059	0.085	0.085	0.110	0.159
2	-0.067	-0.028	-0.009	-0.009	0.010	0.048

Supplementary Table 8: Difference in probability of infection in each study period

irrespective of household size. Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

Study period	Household size	2.5%	25%	50%	Mean	75%	97.5%
1	2	-0.143	0.000	0.286	0.053	0.143	0.286
1	3	0.000	0.092	0.276	0.139	0.184	0.276
1	4	0.003	0.087	0.249	0.128	0.170	0.249

·	All rights reserved. No reuse allowed without permission.						
1	6	-0.120	0.030	0.326	0.103	0.189	0.326
1	7	-0.231	-0.077	0.308	0.024	0.077	0.308
2	2	-0.118	-0.059	0.075	-0.008	0.000	0.075
2	3	-0.085	-0.021	0.090	0.001	0.028	0.090
2	4	-0.130	-0.068	0.059	-0.037	-0.006	0.059
2	5	-0.128	-0.052	0.103	-0.013	0.027	0.103
2	6	-0.129	-0.015	0.254	0.059	0.117	0.254
2	7	-0.154	0.000	0.154	0.016	0.077	0.154

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint 1 (which was not certified by peer review) is the autilet funder, who has granted head reading to display the preprint in persentity. All rights reserved. No reuse allowed without permission.

Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size. Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

medRxiv proprint doi: htt Hounischwalchsizertifie	ed b Ngen by ew fiston sello (/tl o All rights reserved. No	369; this version posted June 14 wh c hasi blantedomea®tis v a lic reuse allowed without permissi	1, 2022. The copyright holder for this preprir enternal registrate to contraints in perpetuity. on.
2	42	42	0
3	61	64	27
4	80	84	89
5	46	58	59
6	19	29	30
7	6	14	12

Supplementary Table 10: Number of contacts at each household size.

1. Goodrich B GJ, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via

Stan. R package version 2.21.3 ed2022.